MedX Health Corp. Selected by BodyCheck NL to Supply Its SIAscopy(TM) Skin Assessment Technology to Be Integrated in BodyCheck(TM) Testing Kits Internationally

MISSISSAUGA, ON--(Marketwired - October 05, 2015) - MedX Health Corp. ("MedX" or the "Company") (TSX VENTURE: MDX), a leading medical device company, announced it has completed an agreement to become the exclusive supplier of skin assessment technology to BodyCheck NL for the supply of its SIAscopy technology within all BodyCheck™ testing kits, currently in the Netherlands, and being marketed internationally.

"We are very excited to be part of the BodyCheck™ service offering and to have the opportunity to participate in the aggressive international growth that BodyCheck NL is working on," said Rob von der Porten, MedX CEO.

"The global mobile health monitoring market is growing rapidly, driven by the rise in communication tools, the growth in 'store & forward' device capability alongside large aging populations and the prevalence of chronic diseases," said Frank Raymakers, BodyCheck, Director of Sales. "We are delighted to add the skin assessment technology offered by MedX to our portfolio of tests," he continued.

About BodyCheck

BodyCheck NL is a privately held company headquartered in the Netherlands, currently operating testing locations nationwide in the Netherlands where the public can arrange on-demand tests. BodyCheck™ also utilizes its mobile testing systems in visits to corporations and other facilities to bring critical health tests to the public. Its proprietary technology currently incorporates analyses of patients' heart, heart rhythm disorders, blood pressure, the absorption of oxygen in blood, diabetes, cholesterol, COPD, lung function, composition of the body, sleep apnea and stress, and going forward will offer skin assessment. The tests are reviewed by cardiologists, physicians and dermatologists who advise on the best course of action. For more information on BodyCheck NL and its products visit http://mijnbodycheck.nl/.

About MedX

MedX, headquartered in Mississauga, Ontario, is a leading medical device company focused on skin cancer; it manufactures and distributes SIMSYS™ and MoleMate™, hand-held devices that use patented technology utilizing light and its remittance to view beneath suspicious moles and lesions in a pain free, non-invasive manner, creating real-time images for physicians and dermatologists to evaluate all types of moles or lesions within seconds. The devices are sold to physicians and clinics, as well as being deployed in drugstore settings where the images are sent remotely to dermatologists who perform a diagnosis. These products are Health Canada, FDA (US), ARTG and CE approved for use in Canada, the US, Australia and Europe. MedX also designs, manufactures and distributes quality laser and light therapy technologies for use in numerous medical settings, approved in major jurisdictions, to provide drug free and non- invasive treatment of tissue damage and pain. For more information and a complete profile of MedX and its products visit www.medxhealth.com.

This press release does not constitute an offer of any securities for sale. This press release contains certain forward-looking statements within the meaning of applicable Canadian securities legislation. These forward-looking statements involve certain risks and uncertainties that could cause actual results to differ, including, without limitation, the company's limited operating history and history of losses, the inability to successfully obtain further funding, the inability to raise capital on terms acceptable to the company, the inability to compete effectively in the marketplace, the inability to complete the proposed acquisition and such other risks that could cause the actual results to differ materially from those contained in the company's projections or forward-looking statements. All forward looking statements in this press release are based on information available to the company as of the date hereof, and the company undertakes no obligation to update forward-looking statements to reflect events or circumstances occurring after the date of this press release.

Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this press release.